|
|
||||||||
From the Department of Ophthalmology and Visual Sciences, The Chinese University of Hong Kong, Hong Kong.
| Abstract |
|---|
|
|
|---|
METHODS. Three concentrations (0, 0.25, and 2.5 mg/mL) of ICG were applied to ARPE19 cells for 1 minute. After isotonic rinsing, the cells were irradiated with a light beam with a wavelength spectrum from 400 to 800 nm and an output of 1850 lumens for 15 minutes. The cells were collected at timed intervals for the investigation of cell death and expression of stress-response genes by reverse transcription-polymerase chain reaction, immunofluorescence, and Western blot analysis.
RESULTS. After ICG incubation, photoreactive changes were observed in the RPE cells. A reduction in cellular viability and considerable shrinkage of the cells were observed. The expressions of the apoptosis-related genes p53 and bax and the cell cycle arrest protein p21 were upregulated in cells treated with both ICG and light. Of the early-response genes, the expression of c-fos was specifically enhanced by light, with additive effects from the presence of ICG. Such stimulatory effects on these gene expressions were greater at 2.5 mg/mL than at 0.25 mg/mL ICG.
CONCLUSIONS. ICG in the presence of acute illumination can elicit cell-cycle arrest and even apoptosis in RPE cells. The establishment of a safety level in the application of ICG in the region of 0.25 mg/mL is recommended.
Recently, ICG has been used for selective staining of the transparent retinal inner limiting membrane (ILM), because of its efficient and complete removal during intraocular surgery.9 10 The procedure is assisted by intraoperative endoillumination with a high level of light intensity. Accordingly, photodynamic damage to retinal cells, including photoreceptors and retinal pigment epithelial (RPE) cells, is possible although not affirmed. The toxicity may cause atrophy of the RPE over the bases of macular holes. Such atrophy is probably related to the amount of ICG used and the scale and duration of endoillumination.11 After its intraocular administration for macular hole surgery, persistent ICG fluorescence was found after 6 weeks.12 This suggested possibly incomplete removal of the dye. In cultured human RPE cells, mitochondrial dehydrogenase activity was decreased after exposure to ICG, with and without illumination, indicating possible dye-induced cellular alteration, even though no histologic or ultrastructural effects were evident.13 Intravitreous injection of ICG into rabbits causes retinal toxicity signaled by consistent morphologic changes in the RPE, formation of vacuoles in ganglion cells, and intraocular inflammation.14 Meanwhile, phototoxicity has been reported in cultured RPE cells in which apoptosis or necrosis has been induced by blue light in an intensity-dependent manner.15 16 Because the inclusion of free radical scavengers can alleviate the situation, involvement of a photooxidative mechanism has been suggested.16 17 In cultured HaCaT keratinocytes, diode laser irradiation in the presence of ICG at concentrations higher than 10 µM is lethal to the cells, with the cell death probably mediated by a photodynamic mechanism.18 The cell-killing effect is probably photo-oxidative and does not involve thermal damage to cellular ultrastructure, as revealed by electronic microscopy.19 It is noted that very few of these ICG phototoxicity studies involved human RPE cells, except the study by Sippy et al.13
In this study, we sought to investigate the biological effects on human RPE cells of a combination of ICG and acute illumination. We used nonpigmented ARPE19 cells to define the photodynamic reactivity of ICG clearly, eliminating any possible interference caused by endogenous pigmentation. With the reduction of cell viability and upregulation of genes relating to apoptosis and cell-cycle arrest, we hypothesize the induction of cell cycle arrest and apoptosis in RPE cells by such treatment.
| Materials and Methods |
|---|
|
|
|---|
Drug Treatment and Exposure to Light
Indocyanine green (ICG) for injection (Diagnogreen) was obtained from Daiichi Pharmaceutical (Tokyo, Japan) and reconstituted with the provided solvent 3 minutes before use. The cells were washed twice with 0.01 M phosphate-buffered saline (PBS) and incubated in 0.25 and 2.5 mg/mL ICG in PBS (denoted hereafter ICG-0.25 and ICG-2.5, respectively) for 1 minute. The dye-free samples did not contain ICG (denoted ICG-0). After a wash in PBS, the cells were placed in fresh culture medium in the dark and subjected to acute exposure to light with a standard endoillumination probe connected to a light source (Hexon Illumination System with ultraviolet impermeable diffuser, model 1266 XII; Dorc, Phoenix, AZ) with an emission spectrum from 400 to 800 nm, irradiance of 1850 lumens, and temperature maintained at 4700 K. The probe was positioned at 1 cm above the cells, so that they were evenly exposed for 15 minutes at 37°C. After illumination, the cells were washed, culture medium was added, and cultures were maintained at 37°C with 5% CO2 balanced with air. The culture medium was refreshed every 2 days. Samples receiving no light served as the control.
Cell Viability Assay
ARPE19 cells in a density of 5 x 104 cells/mL were seeded on 24-well plates (Corning, Acton, MA) and treated as described earlier. A count of viable cells was performed with trypan blue staining every 24 hours. The percentage of viability was calculated as the number of trypan blue-unstained cells against the total number of cells.
Gene Expression Study
Sample Collection.
Samples of ARPE19 cells after light and ICG treatment were collected at 0, 10, 20, 30, 40, 50, 90, and 120 minutes for isolation of RNA and at 0, 4, 8, 12, 16, 24, 48, and 96 hours for Western blot analysis. For immunochemistry, the cells were harvested and fixed at appropriate timed intervals after treatment.
RNA Isolation, cDNA Synthesis, Standardization, and PCR.
Total RNA was extracted with a kit (RNeasy; Qiagen, Valencia, CA). Cells in lysis buffer containing 1% ß-mercaptoethanol (Sigma, St. Louis, MO) were passed through a separation column (QIAShredder; Qiagen), and total RNA was obtained according to the suppliers protocol. Reverse transcription was performed on 500 ng total RNA, with 10 ng/mL random primers and enzyme (SuperScript; Gibco). cDNA corresponding to 5, 10, 15, and 20 ng of total RNA was amplified with primers specific to glyceraldehyde-3-phosphate dehydrogenase (GAPDH) for 25 cycles. The PCR products were separated on 2% agarose gel and quantified with an image analyzer (Gel Doc Quantity One; BioRad, Hercules, CA). The linear range of amplification was determined by plotting the amount of cDNA used in PCR against the optical density of the products. Standardized cDNAs corresponding to 10 ng of total RNA were used, because this amount provides exponential amplification under our PCR conditions. The cDNAs were amplified with the following primer pairs: GAPDH forward: 5'-gaa ggt gaa ggt cgg agt-3', and reverse: 5'-gaa gat ggt gat ggg att tc-3'; p53 forward: 5'-ttg ccg tcc caa gca atg gat ga-3', and reverse: 5'-tct ggg aag gga cag aag atg ac-3'; c-jun forward: 5'-gtg acg gac tgt tct atg act g-3', and reverse: 5'-ggg ggt cgg cgt ggt ggt gat g-3'; c-fos forward: 5'-aga cag acc aac tag aag atg a-3', and reverse: 5'-agc tct gtg gcc atg ggc ccc-3'. The amplification products were separated on 2% agarose gel and stained with 0.5 µg/mL ethidium bromide, and band intensity was scanned. The band intensity of each reaction was normalized against that of GAPDH. Each set of experiments was repeated in triplicate to obtain the mean ± SD.
Immunochemistry.
ARPE19 cells were grown on glass coverslips precoated with 0.1% bovine serum albumin (Sigma), 10 ng/mL fibronectin (Gibco), and 10 ng/mL laminin (Gibco). After incubation with ICG and illumination, cell samples were collected at 24 hours and fixed with 4% buffered paraformaldehyde (Sigma) at pH 7.40. After retrieval of the antigen by 0.05% trypsin (pH 7.20) and blocking with 5% normal goat serum (Gibco), the cells were incubated with antibodies against human bax, p53, and p21 (Santa Cruz Biotechnology, Inc., Santa Cruz, CA). Staining was detected by immunofluorescence (secondary antibodies obtained from Amersham, Busks, UK and nuclear counterstaining with 4',6'-diamino-2-phenylindole [DAPI]; Sigma) or by the avidin-biotin complex method (Vector Laboratories, Burlingame, CA) and observed under fluorescence and light microscopes (Carl Zeiss, Oberkochen, Germany). The staining intensity was graded from 0 to 5+ (low to high). The number of positively stained cells was counted in five optical fields (each 200 µm in diameter) and the frequency was obtained as the ratio of the number of positive cells against the total number of cells.
Western Blot Analysis on Total Soluble Protein.
ARPE19 cells after ICG and illumination were counted, and 108 cells were lysed in 1 mL buffer containing 50 mM Tris-HCl (pH 7.40), 10 mM MgSO4, 1 mM EDTA.Na2 [pH 8.0], 1 mM DL-dithiothreitol [Sigma], 1 mM phenylmethylsulfonyl fluoride [Sigma], and protease inhibitor mix [Sigma]) on ice. After sonication, the samples were mixed in equal volume with urea-sodium dodecyl sulfate (SDS) buffer (9 M urea, 125 mM Tris-HCl [pH 6.8], 4% SDS, 15% glycerol, and 0.1% ß-mercaptoethanol) and denatured at 95°C for 5 minutes. The samples (equivalent to 5 x 105 cells) were resolved in 10% denaturing SDS-polyacrylamide gel electrophoresis at 200 volt-hours (Vh). The protein profile was transblotted to nitrocellulose membrane (Amersham) at 100 Vh at 4°C. After blocking with 10% skimmed milk in Tris-buffered saline containing 0.05% Tween 20, the membrane was incubated with antibody against human bax (Santa Cruz). The signal was revealed by incubation with Ig-horseradish peroxidase conjugate (Amersham) and detected by enhanced chemiluminescence (Amersham).
| Results |
|---|
|
|
|---|
|
|
|
|
|
|
|
Expression of Early Response Genes Leading to Cell Death.
c-Fos and c-Jun are major components of AP-1, which is commonly activated in cell death. In this study, the level of c-Fos RNA in RPE cells increased at 10 minutes after illumination (Fig. 3) . The level at 20 to 40 minutes was approximately 12 times that in the cells without illumination (quantitative data shown in Figs. 4B 4C ). In the illuminated ICG-2.5 cells, the expression was increased to approximately 16-fold at 20 minutes, and gradually returned to basal level after 2 hours. In ICG-0.25 cells, the light reaction induced approximately a 14-fold increase, whereas there was also a 12-fold upregulation in dye-free samples. Without light, c-fos expression was greatly inhibited (Figs. 4B 4C) . In contrast to c-Fos, the RNA levels of c-Jun were constant in all samples, indicating that expression of c-Jun was not affected by the concentration of ICG and exposure to light (Fig. 3) .
| Discussion |
|---|
|
|
|---|
Our experiments showed altered gene expression in ARPE19 cells after treatment with ICG and illumination. ICG has been used in staining the ILM for easy removal, which contributes to high closure rates in macular hole surgery.8 10 At times, repeat applications are needed to ensure adequate ILM staining.8 27 This has been an established ophthalmic surgical technique for some years, but there are only a few studies examining the direct effects on retinal cells of ICG combined with acute illumination.13 A decrease in mitochondrial dehydrogenase indicates the possible risk of RPE cell damage when the cells are directly exposed to ICG at the base of macular holes. Phototoxicity of ICG had been shown in other cell systems, such as HaCaT18 and colon cancer cells,28 where ICG was lethal to cells when combined with diode laser irradiation. ICGs cytotoxic effects included cytoplasmic vesiculation, dilation of rough endoplasmic reticulum, Golgi apparatus, perinuclear cisternae, and chromatin condensation in the nucleus.19 Cumulative cellular ICG uptake involved the organic anion transporting polypeptide and cytoplasmic binding of dye molecules to glutathione S-transferase.19 Increase of bax and noticeable abatement of bcl-XL expression indicating apoptosis in human leukemia cells resulted after infrared diode laser photostimulation of ICG.29 To help assess the safety level of ICG, we used two frequently applied intravitreous concentrations of ICG (0.25 and 2.5 mg/mL) in our experiments. The ARPE19 cells in our study showed dose-dependent responses to ICG combined with illumination, the reduction of cell viability and the shrinkage of cells, indicating the possibility of cell death. Meanwhile, after incubation with ICG, we found traces of dye present in RPE cytosol and cell membrane, even after extensive washing. For macular hole surgery, ICG fluorescence remained present 6 weeks after administration.12 Although ICG is said to be safe for use in humans, it could be a risk factor for retinal damage, dependent on its concentration, change in osmolarity, pH, and duration of contact.30 Reduced activity of the mitochondrial dehydrogenase in cultured RPE cells also potentiates the toxic effect of ICG.13
In the current study, we examined the expression of p53 and its downstream proteins, bax and p21, to investigate the occurrence of cell death and cycle arrest after the treatment.31 32 33 The expression of p53 was enhanced in ICG-2.5 cells within the first 30 minutes after illumination. p53 restricts cell proliferation by inducing G1 arrest and controlling entry into mitosis.34 The mechanism involves the inhibition of cyclin-dependent Cdc2 kinase that is required to enter mitosis. Cdc2 kinase is simultaneously inhibited by gadd45, p21, and 14-3-3
, which are also transcriptional targets of p53.25 35 36 The upregulation in p53 RNA can be due to its promoted transcription or increase in the half-life of RNA, resulting in an accumulation of p53 protein.25 37 Nuclear translocation of p53 protein also indicates its reactivity in DNA damage (Figs. 5B 5C) . A significant increase in the number of cells positive for nuclear p53 was found in the illuminated ICG-2.5 cells. The stress-induced phosphorylation of p53 protein has been coordinated for its retention inside the nucleus where it is able to function as a master transcription factor.33 The predominant cytoplasmic localization of p53 in the illuminated ICG-0.25 cells suggests its sequestration and likely inactivation.38 39 Thus, in terms of apoptosis-related gene expression, ICG at the low level of 0.25 mg/mL should be considered safe for use.
The pathway of p53-mediated apoptosis is linear, involving bax transactivation.40 41 Bax conveys p53 downstream signal to the release of cytochrome c from mitochondria to activate caspases, which proteolytically splice proteins involved in important cellular functions.42 43 Our blot analysis result showed a time-dependent increase in bax protein after treatment with 2.5 mg/mL ICG. This effect was amplified in the presence of light (Fig. 6A) . Without light, reduced intensity of bax was observed in ICG-2.5 samples after normalization with the expression of the control ß-actin (Fig. 6B) . This suggests that light can have an additive effect on the ICG-induced expression of bax. Overexpression of bax protein promotes RPE apoptotic cell death.32 44 Thus, upregulation of bax in the present study suggests committed entry into apoptosis. Also, immunostaining indicated bax protein migration from a pattern of cytosolic dispersion to aggregation (Figs. 5E 5F) . The speckled distribution may be due to the predominant localization of bax protein to the cytoplasmic organelles, such as mitochondria. Because bax and other proteins in the bcl-2 family contain transmembrane domains, they reside in the outer mitochondrial membrane and are involved in the regulation of mitochondrial permeability, which controls the passage of such proapoptotic factors as cytochrome c into the cytoplasm.42 43 Also, the cytotoxicity of ICG in RPE cells has been shown to be linked to reduction in mitochondrial enzymes.13
Our study presents evidence of RPE cell arrest by the increase in expression of p21, indicating the concordance of p53 and its transcriptional activity on the regulation of p21.34 p21 protein is an inhibitor capable of silencing the cyclin-dependent kinases (Cdks) and arresting the cells in the G0-G1 phase.33 45 It also promotes assembly of cyclin-Cdk.31 Binding of p21 to proliferating cell nuclear antigen blocks its association with DNA polymerases, thus inhibiting DNA synthesis.46 47 The elevation of p21 in ARPE19 cells treated with ICG and light could suggest the constraint of cell cycle progression or induction of transient arrest in G1, making room for repair of DNA. As a result, cell growth could be retarded.
Another mechanism of the stress response is through activation of AP-1. AP-1 regulates the expression of its components c-jun or Fra-1, CD44 or E-cadherin, and p53.48 49 c-Fos, a nuclear proto-oncogene protein, forms linkages with c-Jun/AP-1 transcriptional factor.50 51 After translation, these proteins regulate gene transcription by binding to the AP-1 sites of target genes. Our results illustrate an immediate upregulation in c-Fos expression after illumination, reaching a 10-fold increase when compared with the control. As in other cell systems, this immediate induction is regulated at the transcriptional level and the transient feature is due to the autocatalyzed shutoff of transcription and the rapid turnover of c-Fos mRNA.52 We showed the consistent pattern of c-Fos expression after illumination, which was not affected by varying the ICG doses (Fig. 4B) . Without ilumination, there was no detectable alteration (Fig. 4C) . In contrast, expression of c-Jun remained at a consistent level and was not affected by either light or ICG. This suggests a critical role played by c-Fos as an early-response molecule in initiating the inter- or intracellular signaling cascade.
Although it has been reported that light alone is detrimental to the survival of RPE cells in culture,17 we showed the phototoxicity of ICG residue in RPE cells, in that the effects of combined light and ICG treatment were greater. Without ICG, light caused only a minor fluctuation in gene expression (except c-fos). However, light exposure with a high dose of ICG led to more reduction in cell viability and a tendency toward cell death. The ICG molecule appears to act as a photoinitiator or transducer. The dye can assist the visualization of vitreomacular structures in intraocular surgery. However, ICG molecules can access the RPE cell layer during vitrectomy, thus increasing the risk of surrounding cell damages. Our work illustrates ICGs dose-dependent phototoxicity causing cell cycle arrest and apoptosis. We suggest that the safest dose of ICG is as low as 0.25 mg/mL. Moreover, complete removal of dye at the end of an operative procedure is recommended to prevent any detrimental changes in RPE cells and possibly in other cell types.
| Footnotes |
|---|
Submitted for publication November 7, 2001; revised June 24, 2002; accepted July 8, 2002.
Commercial relationships policy: N.
The publication costs of this article were defrayed in part by page charge payment. This article must therefore be marked "advertisement" in accordance with 18 U.S.C.
1734 solely to indicate this fact.
Corresponding author: Chi Pui Pang, Department of Ophthalmology and Visual Sciences, The Chinese University of Hong Kong, Hong Kong Eye Hospital, 147K Argyle Street, Kowloon, Hong Kong; cppang{at}cuhk.edu.hk.
| References |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
S. Kawahara, Y. Hata, M. Miura, T. Kita, A. Sengoku, S. Nakao, Y. Mochizuki, H. Enaida, A. Ueno, A. Hafezi-Moghadam, et al. Intracellular Events in Retinal Glial Cells Exposed to ICG and BBG Invest. Ophthalmol. Vis. Sci., October 1, 2007; 48(10): 4426 - 4432. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Collaer and P. Stalmans Which colour suits the vitreoretinal surgeon? Br. J. Ophthalmol., September 1, 2007; 91(9): 1101 - 1102. [Full Text] [PDF] |
||||
![]() |
P. Saikia, T. Maisch, K. Kobuch, T. L. Jackson, W. Baumler, R.-M. Szeimies, V.-P. Gabel, and J. Hillenkamp Safety Testing of Indocyanine Green in an Ex Vivo Porcine Retina Model Invest. Ophthalmol. Vis. Sci., November 1, 2006; 47(11): 4998 - 5003. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Goldstein, E. Zemel, A. Loewenstein, and I. Perlman Retinal Toxicity of Indocyanine Green in Albino Rabbits Invest. Ophthalmol. Vis. Sci., May 1, 2006; 47(5): 2100 - 2107. [Abstract] [Full Text] [PDF] |
||||
![]() |
H K F Yip, T Y Y Lai, K-F So, and A K H Kwok Retinal ganglion cells toxicity caused by photosensitising effects of intravitreal indocyanine green with illumination in rat eyes Br. J. Ophthalmol., January 1, 2006; 90(1): 99 - 102. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Haritoglou, A. Yu, W. Freyer, S. G. Priglinger, C. Alge, K. Eibl, C. A. May, U. Welge-Luessen, and A. Kampik An Evaluation of Novel Vital Dyes for Intraocular Surgery Invest. Ophthalmol. Vis. Sci., September 1, 2005; 46(9): 3315 - 3322. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Ikagawa, M. Yoneda, M. Iwaki, Z. Isogai, K. Tsujii, R. Yamazaki, T. Kamiya, and M. Zako Chemical Toxicity of Indocyanine Green Damages Retinal Pigment Epithelium Invest. Ophthalmol. Vis. Sci., July 1, 2005; 46(7): 2531 - 2539. [Abstract] [Full Text] [PDF] |
||||
![]() |
A K H Kwok, T Y Y Lai, C-K Yeung, Y-S Yeung, W W Y Li, and S W Chiang The effects of indocyanine green and endoillumination on rabbit retina: an electroretinographic and histological study Br. J. Ophthalmol., July 1, 2005; 89(7): 897 - 900. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Haritoglou, S. Priglinger, A. Gandorfer, U. Welge-Lussen, and A. Kampik Histology of the Vitreoretinal Interface after Indocyanine Green Staining of the ILM, with Illumination Using a Halogen and Xenon Light Source Invest. Ophthalmol. Vis. Sci., April 1, 2005; 46(4): 1468 - 1472. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. L. Jackson, B. Vote, B. C. Knight, A. El-Amir, M. R. Stanford, and J. Marshall Safety Testing of Infracyanine Green Using Retinal Pigment Epithelium and Glial Cell Cultures Invest. Ophthalmol. Vis. Sci., October 1, 2004; 45(10): 3697 - 3703. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. L. Jackson, J. Hillenkamp, B. C. Knight, J.-J. Zhang, D. Thomas, M. R. Stanford, and J. Marshall Safety Testing of Indocyanine Green and Trypan Blue Using Retinal Pigment Epithelium and Glial Cell Cultures Invest. Ophthalmol. Vis. Sci., August 1, 2004; 45(8): 2778 - 2785. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. L. Kindzelskii, V. M. Elner, S. G. Elner, D. Yang, B. A. Hughes, and H. R. Petty Toll-Like Receptor 4 (TLR4) of Retinal Pigment Epithelial Cells Participates in Transmembrane Signaling in Response to Photoreceptor Outer Segments J. Gen. Physiol., July 26, 2004; 124(2): 139 - 149. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Horio and M. Horiguchi Effect on Visual Outcome After Macular Hole Surgery When Staining the Internal Limiting Membrane With Indocyanine Green Dye Arch Ophthalmol, July 1, 2004; 122(7): 992 - 996. [Abstract] [Full Text] [PDF] |
||||
![]() |
J.-D. Ho, H.-C. Chen, S.-N. Chen, and R. J.-F. Tsai Reduction of Indocyanine Green-Associated Photosensitizing Toxicity in Retinal Pigment Epithelium by Sodium Elimination Arch Ophthalmol, June 1, 2004; 122(6): 871 - 878. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Crescenzi, L. Varriale, M. Iovino, A. Chiaviello, B. M. Veneziani, and G. Palumbo Photodynamic therapy with indocyanine green complements and enhances low-dose cisplatin cytotoxicity in MCF-7 breast cancer cells Mol. Cancer Ther., May 1, 2004; 3(5): 537 - 544. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Iriyama, S. Uchida, Y. Yanagi, Y. Tamaki, Y. Inoue, K. Matsuura, K. Kadonosono, and M. Araie Effects of Indocyanine Green on Retinal Ganglion Cells Invest. Ophthalmol. Vis. Sci., March 1, 2004; 45(3): 943 - 947. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Grisanti, P. Szurman, F. Gelisken, S. Aisenbrey, J. Oficjalska-Mlynczak, and K. U. Bartz-Schmidt Histological Findings in Experimental Macular Surgery with Indocyanine Green Invest. Ophthalmol. Vis. Sci., January 1, 2004; 45(1): 282 - 286. [Abstract] [Full Text] [PDF] |
||||
![]() |
A K H Kwok and T Y Y Lai Internal limiting membrane removal in macular hole surgery for severely myopic eyes: a case-control study Br. J. Ophthalmol., July 1, 2003; 87(7): 885 - 889. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |